Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 135 participants.

Also called NCT01541215

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 135 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01541215
  • EudraCT 2011-002605-29
  • CTRI CTRI/2013/10/004082
Other papers using this trial's data
  • Effect of liraglutide treatment on body mass index and weight parameters in children and adolescents with type 2 diabetes: Post hoc analysis of the ellipse trial Pediatric obesity, 2021-08 DOI, PubMed 33634589, PMC8277686 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Austria, Belgium, Brazil, Canada, Croatia, Denmark, Egypt, France, Germany, Greece, Hungary, India, Israel, Italy, Lebanon, Malaysia, Mexico, Morocco, Netherlands, New Zealand, North Macedonia, Norway, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, Spain, Sweden, Taiwan, Thailand, Türkiye, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01541215. Randomized; double masking; primary purpose treatment. Start 2012-11-13 (actual); primary completion 2017-11-15 (actual). Results posted on 2018-12-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes
Acronym
Ellipse™
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
liraglutide
Intervention (Drug)
placebo
Intervention (Drug)
metformin
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01541215
Content hash
cccbdd7042275b23d8aea72124aedb78d1837917b033301ac2d404ad37762fbd